JPRN-UMIN000013815
Recruiting
未知
Clinical study: Early prediction of tumor response using imaging and molecular biomarkers of hormone sensitive breast cancer in neoadjuvant hormonal therapy setting - Imaging and molecular biomarker study of hormone sensitive breast cancer in neoadjuvant hormonal therapy setting
Saitama International Medical Center0 sites30 target enrollmentApril 25, 2014
ConditionsHormonal sensitive breast cancer
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Hormonal sensitive breast cancer
- Sponsor
- Saitama International Medical Center
- Enrollment
- 30
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Patients who have already underwent chemotherapy or hormonal therapy
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 2
A randomised pilot study to investigate the optimum timing of gemcitabine and concurrent radiation therapy after induction gemcitabine and carboplatin for locally advanced non-small cell lung cancerAdvanced non-small cell lung cancerCancer - Lung - Non small cellACTRN12605000169640Princess Alexandra Hospital24
Completed
Not Applicable
To assess response of tumor to chemotherapy given before surgery by using PET CT scan.Health Condition 1: null- Patients taking treatment of cancerCTRI/2014/07/004767ot Applicable75
Completed
Not Applicable
A study to compare two chemotherapy regimens like cisplatin&etoposide vs paclitaxel&carboplatin with concurrent RT in non small cell lung cancersHealth Condition 1: C349- Malignant neoplasm of unspecifiedpart of bronchus or lungCTRI/2021/09/036500svims tirupati34
Not yet recruiting
Not Applicable
Predicting tumor response to neoadjuvant chemotherapy in esophageal cancer patients-correlation between hypoxic imaging and signal transduction pathwaysesophageal cancerJPRN-UMIN000045299Institute of Advanced Clinical Medicine, Kindai University40
Completed
Not Applicable
Anti-tumor efficacy of TAGRISSO (Osimertinib) in NSCLC Patients in Whom T790 Mutations Are Detected by Liquid Biopsy Using BALF, Plasma or Pleural EffusioNeoplasmsKCT0003232Asan Medical Center63